News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Join Forces in $7 Billion Deal for Amylin Pharmaceuticals, Inc. (AMLN)


7/2/2012 6:41:00 AM

Bristol-Myers Squibb Co. (NASDAQ:BMY) and AstraZeneca plc (NYSE:AZN) have teamed up to execute a uniquely structured takeover of diabetes firm Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) for a total value of $7 billion - the fourth and largest billion-dollar-plus deal of 2012.

Amylin's assets include GLP-1 agonists Byetta (exenatide) and its extended release equivalent Bydureon, Metreleptin, and Symlin (pramlintide acetate) and has been on the market for acquisition for some time.

Read at BusinessWeek
Read at News-Medical
Read at Reuters
Read at Washington Post
Read at Wall Street Journal
Read at BioWorld International
Read at Guardian

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES